FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic cancer. METHODS: We randomly assigned 493 patients with resected pancreatic ductal adenocarcinoma to receive a modified FOLFIRINOX regimen (oxaliplatin [85 mg per square meter of body-surface area], irinotecan [180 mg per square meter, reduced to 150 mg per square meter after a protocol-specified safety analysis], leucovorin [400 mg per square meter], and fluorouracil [2400 mg per square meter] every 2 weeks) or gemcitabine (1000 mg per square meter on days 1, 8, and 15 every 4 weeks) for 24 weeks. The primary end point was disease-free survival. Secondary end points included overall survival and safety. RESULTS: At a median follow-up of 33.6 months, the median disease-free survival was 21.6 months in the modified-FOLFIRINOX group and 12.8 months in the gemcitabine group (stratified hazard ratio for cancer-related event, second cancer, or death, 0.58; 95% confidence interval [CI], 0.46 to 0.73; P<0.001). The disease-free survival rate at 3 years was 39.7% in the modified-FOLFIRINOX group and 21.4% in the gemcitabine group. The median overall survival was 54.4 months in the modified-FOLFIRINOX group and 35.0 months in the gemcitabine group (stratified hazard ratio for death, 0.64; 95% CI, 0.48 to 0.86; P=0.003). The overall survival rate at 3 years was 63.4% in the modified-FOLFIRINOX group and 48.6% in the gemcitabine group. Adverse events of grade 3 or 4 occurred in 75.9% of the patients in the modified-FOLFIRINOX group and in 52.9% of those in the gemcitabine group. One patient in the gemcitabine group died from toxic effects (interstitial pneumonitis). CONCLUSIONS: Adjuvant therapy with a modified FOLFIRINOX regimen led to significantly longer survival than gemcitabine among patients with resected pancreatic cancer, at the expense of a higher incidence of toxic effects. (Funded by R&D Unicancer and others; ClinicalTrials.gov number, NCT01526135 ; EudraCT number, 2011-002026-52 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Polychemotherapy, either with 5-fluorouracil (5-FU), irinotecan and oxaliplatin in combination with folinic acid (FOLFIRINOX), or with gemcitabine and nab-paclitaxel (GnP), is considered the standard of care for patients suffering from metastatic PDAC (mPDAC)3,4.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
In the citing paper
“Less than half of all patients respond to the primary treatment for PDAC, chemotherapy3,4”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer
Neoptolemos, J. P., Stocken, D. D., Friess, H., Bassi, C., Dunn, J. A., Hickey, H., Beger, H., Fernandez-Cruz, L., Dervenis, C., Lacaine, F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032295 · Cited by 2,716
Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,419
Neoptolemos, J. P., Palmer, D. H., Ghaneh, P., Psarelli, E. E., Valle, J. W., Halloran, C. M., Faluyi, O., O'Reilly, D. A., Cunningham, D., Wadsley, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32409-6 · Cited by 1,926
Self-citationOettle, H., Neuhaus, P., Hochhaus, A., Hartmann, J. T., Gellert, K., Ridwelski, K., Niedergethmann, M., Zülke, C., Fahlke, J., Arning, M. B., et al. (2013) · JAMA · doi:10.1001/jama.2013.279201 · Cited by 1,794
Research works printed but not linked: 1
- Early Breast Cancer Trialists’ Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985–1990. Oxford England: Oxford University Press 1990.
Cited by
Items 801–900 of 1,002
Yang, P.-C., Huang, K., Pua, U., Kim, M. D., Li, S., Li, X.-Y., & Liang, P. (2019) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2019.12.006 · Cited by 17
Warschkow, R., Tsai, C., Köhn, N., Erdem, S., Schmied, B. M., Nussbaum, D. P., Gloor, B., Müller, S., Blazer, D. G., & Worni, M. (2020) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-020-01859-2 · Cited by 18
Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts
Bulle, A. S., Dekervel, J., Deschuttere, L., Nittner, D., Cutsem, E. V., Verslype, C., & van Pelt, J. F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s245134 · Cited by 20
Jung, J. H., Shin, D. W., Kim, J., Lee, J.-C., & Hwang, J. (2020) · Cancers · doi:10.3390/cancers12113137 · Cited by 20
“Moreover, in 2019, modified FOLFIRINOX became a new a milestone in the adjuvant setting of resectable PC; consequently, the regimen is becoming more widely used [6].”
BackgroundPancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?
Montemagno, C., Cassim, S., Leiris, N. D., Durivault, J., Faraggi, M., & Pagès, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126413 · Cited by 18
Wu, Y. H. A., Oba, A., Lin, R., Watanabe, S., Meguid, C. L., Schulick, R. D., & Chiaro, M. D. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-21-119 · Cited by 17
“Within the last decade, the introduction of FOLFIRINOX and GnP has played a significant role in improving the overall survival of PC patients (5,6,13), as LAPC patients would more likely become operable after undergoing more effective chemotherapy treatment (14-19).”
BackgroundMaeda, S., Mederos, M. A., Chawla, A., Moore, A. M., Shoucair, S., Yin, L., Burkhart, R. A., Cameron, J. L., Park, J. Y., Girgis, M. D., et al. (2021) · Surgery · doi:10.1016/j.surg.2021.10.015 · Cited by 18
Korpela, T., Ristimaki, A. P., Udd, M., Vuorela, T., Mustonen, H. K., Haglund, C. H., Kylänpää, L., & Seppänen, H. E. (2022) · BMC Cancer · doi:10.1186/s12885-021-09080-0 · Cited by 19
“In addition, current adjuvant therapies provide only a modest improvement in the overall survival (OS) due to serious chemoresistance [5].”
BackgroundNeoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
Gartrell, R. D., Enzler, T., Kim, P., Fullerton, B. T., Fazlollahi, L., Chen, A., Minns, H. E., Perni, S., Weisberg, S. P., Rizk, E. M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2066767 · Cited by 23
“Of numerous available systemic therapies, only FOLFIRINOX [fluorouracil, leucovorin, irinotecan, oxaliplatin] and gemcitabine with capecitabine have demonstrated a significant improvement in overall survival (OS) in the adjuvant setting.(5,6) More recently, preoperative delivery of therapy in PDAC has gained momentum…”
BackgroundPancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy
Dai, H., Abdullah, R., Wu, X., Li, F., Ma, Y., Lü, A., & Zhang, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.855474 · Cited by 22
Lee, W., Song, G., & Bae, H. (2022) · Antioxidants · doi:10.3390/antiox11091714 · Cited by 16
“The combination of 5-FU, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) regimen is effective against advanced PDAC, but the adverse effects are more severe than those of gemcitabine [12].”
BackgroundGiorgio, C. D., Lupia, A., Marchianò, S., Bordoni, M., Bellini, R., Massa, C., Urbani, G., Roselli, R., Moraca, F., Sepe, V., et al. (2022) · Cells · doi:10.3390/cells11213482 · Cited by 20
“The clinical management of PDAC remains suboptimal, and although surgery in combination with adjuvant chemotherapy shows efficacy for stage I and II, only 10–15% of patients are diagnosed with resectable disease [10].”
BackgroundMesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges
Ma, Z., Hua, J., Liu, J., Zhang, B., Wang, W., Yu, X., & Xu, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043559 · Cited by 20
“Currently, gemcitabine and albumin-bound paclitaxel or modified FOLFIRINOX is still the standard first-line therapy for metastatic patients [3,7,33,34].”
BackgroundRefining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival
Bailey, P. J., Zhou, X., An, J., Peccerella, T., Hu, K., Springfeld, C., Büchler, M. W., & Neoptolemos, J. P. (2023) · Function · doi:10.1093/function/zqad011 · Cited by 20
Sex-Related Differences in Pancreatic Ductal Adenocarcinoma Progression and Response to Therapy
Grahovac, J., Djurić, A., Tanić, M., & Krivokuća, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312669 · Cited by 20
“Also, the patients in the FOLFIRINOX group had 54.4 months of median overall survival compared to 35.0 months in the GEN group, but sex differences were not considered [124] (NCT01526135).”
InfluentialWolfe, A. R., Wald, P., Webb, A., Sebastian, N., Walston, S., Robb, R. N., Chen, W., Vedaie, M., Dillhoff, M. E., Frankel, W. L., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27496 · Cited by 16
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer
Blaauboer, A., Booy, S., van Koetsveld, P. M., Karels, B., Dogan, F., van Zwienen, S., van Eijck, C. H. J., & Hofland, L. J. (2020) · BMC Cancer · doi:10.1186/s12885-020-07420-0 · Cited by 18
Recent advances in immunotherapy for pancreatic cancer
Chi, J., Patel, R., Rehman, H., Goyal, S. P., & Saif, M. W. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.90 · Cited by 18
“OS has improved with the addition of chemotherapy in the adjuvant setting as well, however, there is much room for improvement([13,14]).”
BackgroundYang, S., Lu, L., Kao, H., Chen, B., Kuo, T., Kuo, S., Tien, Y., Bai, L., Cheng, A., & Yeh, K. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1973710 · Cited by 17
Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice
Inman, K. S., Liu, Y., Scotti, M. L., Leitges, M., Krishna, M., Crawford, H. C., Fields, A. P., & Murray, N. R. (2022) · Cancers · doi:10.3390/cancers14030796 · Cited by 17
“response, in most cases only prolonging patient survival by a matter of weeks to months [2].”
BackgroundTurner, K. M., Delman, A. M., Ammann, A. M., Sohal, D. P. S., Olowokure, O. O., Choe, K. A., Smith, M. T., Kharofa, J. R., Ahmad, S. A., Wilson, G. C., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11580-7 · Cited by 16
“single agent chemotherapy regimens.(15) Perhaps due to these findings and the difficulty in administering chemotherapy in the postoperative period, patients with favorable pathology have a 15–35% lower chance of receiving AC.”
BackgroundGolesworthy, B., Wang, Y., Tanti, A., Pacis, A., Romero, J. M., Cuggia, A., Domecq, C., Bourdel, G., Denroche, R. E., Jang, G. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860767 · Cited by 17
Yang, Y., Ren, L., Li, S., Zheng, X., Liu, J., Wan, L., Fu, W., Wang, J., & Du, G. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-2021 · Cited by 16
“Surgical resection is the only potential curative treatment for pancreatic cancer at present and adjuvant chemotherapies have improved patient outcomes, but at the cost of a higher incidence of adverse effect (3,4).”
BackgroundChristopher, W. O., Nassoiy, S. P., Marcus, R. K., Keller, J. K., Chang, S., Fischer, T. D., Bilchik, A. J., & Goldfarb, M. R. (2022) · HPB · doi:10.1016/j.hpb.2022.05.1344 · Cited by 16
Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies
Osei‐Bordom, D., Serifis, N., Brown, Z. J., Hewitt, D. B., Lawal, G., Sachdeva, G. S., Cloonan, D. J., & Pawlik, T. M. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101803 · Cited by 18
Jing, P., Luo, Y., Chen, Y., Tan, J., Liao, C., & Zhang, S. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.2c00548 · Cited by 16
CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
Arsenijevic, T., Coulonval, K., Raspé, E., Demols, A., Roger, P. P., & Laethem, J. V. (2023) · Cancers · doi:10.3390/cancers15030968 · Cited by 21
Magyar, C. T. J., Vashist, Y. K., Stroka, D., Kim‐Fuchs, C., Berger, M. D., & Banz, V. M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04689-z · Cited by 17
“2013), whereas 5-fluorouracil, irinotecan and oxaliplatin are used for both adjuvant (Conroy et al. 2018) and palliative treatment (Conroy et al.”
BackgroundWhy the Treatment Sequence Matters
Wu, V. S., Elshami, M., Stitzel, H. J., Lee, J. J., Hue, J. J., Kyasaram, R. K., Hardacre, J. M., Ammori, J. B., Winter, J. M., Selfridge, J. E., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000005830 · Cited by 16
Pu, N., Wu, W., Liu, S., Xie, Y., Yin, H., Chen, Q., He, T., Xu, Z., Wang, W., Yu, J., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000589 · Cited by 16
Vidal, L., Pando, E., Blanco, L., Fabregat-Franco, C., Castet, F., Sierra, A., Macarulla, T. M., Balsells, J., Charco, R., & Vivancos, A. P. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102604 · Cited by 17
Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer
Rowell, M., Deschênes‐Simard, X., Lopes‐Paciencia, S., Calvé, B. L., Kalegari, P., Mignacca, L., Ruiz, A. F., Guillon, J., Lessard, F., Bourdeau, V., et al. (2023) · Cell Cycle · doi:10.1080/15384101.2023.2278945 · Cited by 19
“Oxaliplatin, together with irinotecan, 5-fluorouracil, and folinic acid form the drug combination known as FOLFIRINOX, a mainstay systemic therapy against pancreatic cancer [39,40].”
BackgroundMerali, N., Chouari, T. A. M., Terroire, J., Jessel, M.-D., Liu, D., Smith, J.-H., Wooldridge, T., Dhillon, T., Jiménez, J. I., Krell, J., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316888 · Cited by 20
Clinical Utility of the Combined Use of CA19-9 and DUPAN-2 in Pancreatic Adenocarcinoma
Sumiyoshi, T., Uemura, K., Shintakuya, R., Okada, K., Baba, K., Harada, T., Serikawa, M., Ishii, Y., Nakamura, S., Arihiro, K., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15221-z · Cited by 17
Lucocq, J. E., Hawkyard, J., Haugk, B., Mownah, O. A., Menon, K. V., Furukawa, T., Inoue, Y., Hirose, Y., Sasahira, N., Feretis, M., et al. (2024) · British journal of surgery · doi:10.1093/bjs/znae100 · Cited by 23
“The proportion of patients receiving GEM-CAP and FOLFIRINOX increased in the cohort from 2017 onwards ( P 0.001).”
InfluentialTidwell, T., Røsland, G. V., Tronstad, K. J., Søreide, K., & Hagland, H. R. (2024) · Cancer Medicine · doi:10.1002/cam4.7318 · Cited by 17
Zheng, Y., Yang, Y., Xiong, Q., Ma, Y., & Zhu, Q. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011143 · Cited by 21
“However, recent advances in chemotherapy and immunotherapy have yielded limited improvements in PDAC outcomes [4], primarily due to the unique tumor microenvironment characterized by hypoxia and metabolic reprogramming.”
BackgroundLuo, B., An, Q., Lei, J., Tan, D., Liu, X., Li, H., Zhao, Y., Qin, J., Zhang, C., Zhang, Y., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2447821 · Cited by 21
Steen, T. V., Espinoza, I. C., Duran, C., Casadevall, G., Serrano‐Hervás, E., Cuyàs, E., Verdura, S., Kemble, G. W., Kaufmann, S. H., McWilliams, R. R., et al. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101143 · Cited by 20
Xie, L., Xia, L., Klaiber, U., Sachsenmaier, M., Hinz, U., Bergmann, F., Strobel, O., Büchler, M. W., Neoptolemos, J. P., Fortunato, F., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.27399 · Cited by 17
Adjuvant and neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma
Leonhardt, C.-S., Traub, B., Hackert, T., Klaiber, U., Strobel, O., Büchler, M. W., & Neoptolemos, J. P. (2020) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000040 · Cited by 17
Abdallah, R., Taly, V., Zhao, S., Pietrasz, D., Bachet, J., Basile, D., Mas, L., Zaanan, A., Laurent‐Puig, P., & Taïeb, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102028 · Cited by 20
Self-citationKapacee, Z. A., Knox, J. J., Palmer, D. H., Blagden, S. P., Lamarca, Á., Valle, J. W., & McNamara, M. G. (2020) · Medical Oncology · doi:10.1007/s12032-020-01386-6 · Cited by 17
Liu, Y., Awadia, S. S., Delaney, A. M., Sitto, M., Engelke, C. G., Patel, H., Calcaterra, A., Zelenka-Wang, S., Lee, H., Contessa, J. N., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100834 · Cited by 16
Defining and Treating Borderline Resectable Pancreatic Cancer
Perri, G., Prakash, L., & Katz, M. H. G. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00769-1 · Cited by 16
Datta, J., Wilson, G. C., D'Angelica, M. I., Katz, M. H. G., Maithel, S. K., Merchant, N. B., & Ahmad, S. A. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004471 · Cited by 17
“publication of this seminal article.(2-8) Paramount to these developments has been increasingly effective modern combination chemotherapy regimens delivered in the metastatic, adjuvant, and now neoadjuvant settings; safety and technical mastery of pancreatectomy; and growing appreciation of the molecular underpinnings…”
BackgroundAndreou, A., Aeschbacher, P., Candinas, D., & Gloor, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040696 · Cited by 21
“, which included only patients <80 years in the FOLFIRINOX arm [42].”
BackgroundHill, C., Han-Oh, S., Cheng, Z., Wang, K. K., Meyer, J. J., Herman, J. M., & Narang, A. K. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01782-w · Cited by 16
LINC00460 promotes pancreatic cancer progression by sponging miR‐491‐5p
Wu, J., Sun, S., Liao, W., Chen, E., Wang, X., Song, Y., Duan, F., Deng, W., & Li, S. (2021) · The Journal of Gene Medicine · doi:10.1002/jgm.3333 · Cited by 18
Treatment Approach to Adenocarcinoma of the Ampulla of Vater
Patel, M. A., & Uboha, N. V. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00894-5 · Cited by 16
Hue, J. J., Katayama, E., Markt, S. C., Elshami, M., Saltzman, J. N., Bajor, D. L., Hosmer, A. E., Mok, S. R. S., Dumot, J. A., Ammori, J. B., et al. (2021) · Surgery · doi:10.1016/j.surg.2021.10.023 · Cited by 18
Wang, C.-X., Wang, T., Zhang, K.-D., Li, M., Shen, Q., Lu, S., & Zhang, J. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00897-4 · Cited by 16
“Chemotherapy and radiotherapy are currently the major clinical treatment options of PDAC [5].”
BackgroundSeufferlein, T. T. W., Mayerle, J. V., Böck, S., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1771-6811 · Cited by 20
Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer
AlMasri, S. S., Zenati, M. S., Hammad, A. Y., Nassour, I., Liu, H., Hogg, M. E., Zeh, H. J., Boone, B. A., Bahary, N., Singhi, A. D., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.18355 · Cited by 17
Voutsadakis, I. A., & Digklia, A. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-22-108 · Cited by 16
Sakaguchi, T., Satoi, S., Yamamoto, T., Yamaki, S., & Sekimoto, M. (2020) · Surgery Today · doi:10.1007/s00595-020-01963-2 · Cited by 16
Chen, Q., Wei, T., Wang, J., Zhang, Q., Li, J., Zhang, J., Ni, L., Wang, Y., Bai, X., & Liang, T. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.008 · Cited by 16
Vienot, A., Chevalier, H., Bolognini, C., Gherga, E., Klajer, É., Meurisse, A., Jary, M., Kim, S. C. H., d’Engremont, C., Nguyen, T., et al. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i3.332 · Cited by 18
Choi, M., Chong, J. U., Hwang, H. K., Seo, H. I., Yang, K., Ryu, J. H., Roh, Y. H., Kim, D. H., Lee, J. H., Lee, W. J., et al. (2021) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.996 · Cited by 16
Wode, K., Hök Nordberg, J., Kienle, G. S., Elander, N. O., Bernhardson, B.-M., Sunde, B., Sharp, L., Henriksson, R., & Fransson, P. (2020) · Trials · doi:10.1186/s13063-020-04581-y · Cited by 16
“The only option for cure is surgical resection, preferably followed by 6 months of postoperative combination chemotherapy [4, 5].”
BackgroundAdjuvant chemotherapy omission after pancreatic cancer resection: a French nationwide study
Poiraud, C., Lenne, X., Bruandet, A., THEIS, D., Bertrand, N., Turpin, A., Truant, S., & Amrani, M. E. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03393-7 · Cited by 15
“Since the CONKO-001 trial, gemcitabine for 6 months was the recommended regimen after resection until the FOL-FIRINOX regimen became the current standard [3].”
MethodOutcomes following pancreaticoduodenectomy for octogenarians: a systematic review and meta-analysis
Phillipos, J., Lim, K.-Z., Pham, H., Johari, Y., Pilgrim, C. H. C., & Smith, M. (2024) · HPB · doi:10.1016/j.hpb.2024.08.007 · Cited by 15
αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin
Rehm, J., Winzer, R., Pretze, M., Müller, J., Notni, J., Hempel, S., Distler, M., Folprecht, G., & Kotzerke, J. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2024.1487602 · Cited by 15
Yang, S., Ta, Y. N., & Chen, Y. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01908-7 · Cited by 19
“Pancreatic ductal adenocarcinoma (PDAC), the most com - mon form of pancreatic cancer, accounts for over 90% of cases [ 1 ].”
Classic versus innovative strategies for immuno-therapy in pancreatic cancer
Formelli, M. G., Palloni, A., Tavolari, S., Deiana, C., Andrini, E., Marco, M. D., Campana, D., Lamberti, G., & Brandi, G. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115671 · Cited by 20
Tai, D. W.-M., Conroy, T., Lee, J. J. X., Chee, C. E., Hao, C., Wijaya, I., Aggarwal, S., Ueno, M., Jeung, H., Hashim, N. M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.105826 · Cited by 20
“44,45 While S-1 and mFOLFIRINOX have not been compared in the adjuvant setting, they have been assessed in the Korean randomised phase III MPACA-3 trial in the second line setting for patients with metastatic pancreatic cancer who had progressed on gemcitabine where mFOLFIRINOX treatment resulted…”
Self-citationDiscovery of predictive biomarkers for cancer therapy through computational approaches
Wang, X., Nguyen, J., Nader, K. M., Miihkinen, M., Wall, P., Singhal, A., Bedard, P. L., Ideker, T., Aittokallio, T. A., & Haibe‐Kains, B. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01109-8 · Cited by 31
Weniger, M., Moir, J. A. G., Damm, M., Maggino, L., Kordes, M., Rosendahl, J., Ceyhan, G. O., Schorn, S., Schmid, D., D’Haese, J. G., et al. (2020) · Surgical Oncology · doi:10.1016/j.suronc.2020.08.031 · Cited by 15
Luu, A. M., Belyaev, O., Höhn, P., Praktiknjo, M., Janot, M., Uhl, W. H., & Braumann, C. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-433 · Cited by 17
“Recent developments in oncologic treatment have shown significant improvement in overall postoperative survival of 28–54 months (9,10).”
BackgroundTang, R., Meng, Q., Wang, W., Liang, C., Hua, J., Xu, J., Yu, X., & Shi, S. (2021) · Gland Surgery · doi:10.21037/gs-21-16 · Cited by 16
“In fact, compared to the standard of the use of single-agent gemcitabine, the use of multi-agent chemotherapy for both advanced and localized PC has been demonstrated to improve patient survival (42).”
BackgroundhENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Aughton, K., Elander, N. O., Evans, A., Jackson, R., Campbell, F., Costello, E., Halloran, C. M., Mackey, J. R., Scarfe, A. G., Valle, J. W., et al. (2021) · Cancers · doi:10.3390/cancers13225758 · Cited by 16
“Combining gemcitabine or 5-FU with other chemotherapeutics further increases survival, including gemcitabine with capecitabine [11] or 5-FU with FA, irinotecan, and oxaliplatin (FOLFIRINOX) [12].”
BackgroundAntecolic versus retrocolic reconstruction after partial pancreaticoduodenectomy
Hüttner, F. J., Klotz, R., Ulrich, A. B., Büchler, M. W., Probst, P., & Diener, M. K. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011862.pub3 · Cited by 19
Krstić, A., Pavić, A., Avdović, E., Marković, Z., Stevanović, M. J., & Petrović, I. (2022) · Molecules · doi:10.3390/molecules27072115 · Cited by 16
Villano, A. M., O’Halloran, E. A., Goel, N., Ruth, K. J., Barrak, D., Lefton, M. D., & Reddy, S. S. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26906 · Cited by 15
Liu, L., An, X., Schaefer, M., Yan, B., Torre, C. D. L., Hillmer, S., Gladkich, J., & Herr, I. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113511 · Cited by 18
Martin, R. C. G., Schoen, E. C., Philips, P., Egger, M. E., McMasters, K. M., & Scoggins, C. R. (2022) · Surgery · doi:10.1016/j.surg.2022.07.033 · Cited by 15
Akhuba, L. G., Tigai, Z. G., & Shek, D. (2022) · Biomedicines · doi:10.3390/biomedicines10123196 · Cited by 19
“Chemotherapeutic choices of treatment include either modified FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin) [8], gemcitabine monotherapy or gemcitabine in combination with nab-paclitaxel [9].”
BackgroundA Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer
de Geus, S. W. L., & Sachs, T. E. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13281-1 · Cited by 18
“003).(15) Potentially, FOLFIRINOX may further improve outcomes in the neoadjuvant setting.”
BackgroundMethodInhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
Mortoglou, M., Miralles, F., Mould, R. R., Sengupta, D., & Onganer, P. U. (2023) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2023.151318 · Cited by 18
Giuliani, T., Perri, G., Kang, R., & Marchegiani, G. (2023) · Cancers · doi:10.3390/cancers15092499 · Cited by 15
“Newer drug regimens demonstrate a median overall survival of as long as 54 months, compared to 20 months in historical surgery-only cohorts [8,9].”
BackgroundGene signature developed for predicting early relapse and survival in early-stage pancreatic cancer
Huang, L., Yuan, X., Zhao, L., Han, Q., Yan, H., Yuan, J., Guan, S., Xu, X., Dai, G., Wang, J., et al. (2023) · BJS Open · doi:10.1093/bjsopen/zrad031 · Cited by 16
Murimwa, G. Z., Karalis, J. D., Meier, J., Nehrubabu, M., Thornton, M. A., Porembka, M. R., Wang, S. C., Zeh, H. J., Yopp, A. C., & Polanco, P. M. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27357 · Cited by 17
“Incremental improvement in peri‐ and intraoperative management has rendered contemporary pancreatectomy a much safer operation than before, with a more favorable prognosis, and <2% perioperative mortality at high‐volume centers.(7,8) Surgical evaluation by a capable and high‐volume surgeon coupled with multimodality c…”
Jung, K., Choi, S., Song, H., Kwak, K., Anh, S., Jung, J. H., Kim, B., Ahn, J., Kim, J., Hwang, J., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231175441 · Cited by 15
Biagi, J., Cosby, R., Bahl, M., Elfiki, T. A., Goodwin, R. A., Hallet, J. I., Hirmiz, K., & Mahmud, A. (2023) · Current Oncology · doi:10.3390/curroncol30070482 · Cited by 15
“The PRODIGE [25] and ESPAC-4 [26] trials with experimental arms of mFOLFIRINOX and gemcitabine plus capecitabine, respectively, met their study endpoints and have been adopted as new standards.”
MethodResultSelf-citationDoppenberg, D., van Dam, J. L., Han, Y., Bonsing, B. A., Busch, O. R., Festen, S., van der Harst, E., de Hingh, I. H. J. T., Homs, M. Y. V., Kwon, W., et al. (2023) · British journal of surgery · doi:10.1093/bjs/znad210 · Cited by 20
“983 CA19-9 ≤ 500 units/ml 33 of 66 (50) 12 of 61 (20) < 0.”
Emerging Prognostic and Predictive Factors in Pancreatic Cancer
Karamitopoulou, E. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100328 · Cited by 17
Monte, L. B. D., Clemente, F., Ruggiero, E., Pini, R., Ceraolo, M. G., Lena, M. S., Balestrieri, C., Lazarevic, D., Belfiori, G., Crippa, S., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104819 · Cited by 20
Spatial immune composition of tumor microenvironment in patients with pancreatic cancer
Zwart, E. S., van Ee, T., Affandi, A. J., Boyd, L. N. C., Rodríguez, E., den Haan, J. M. M., Sarasqueta, A. F., van Grieken, N. C. T., Meijer, L. L., van Kooyk, Y., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03573-6 · Cited by 16
Belfiori, G., Crippa, S., Pagnanelli, M., Gasparini, G., Aleotti, F., Camisa, P. R., Partelli, S., Pecorelli, N., Stefano, F. D., Lena, M. S., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15105-2 · Cited by 17
“7 In the randomized trial by Conroy et al., 8 there is a 8% rate of cancer relapse at restaging after “curative surgery” before initiating adjuvant therapy.”
Chen, B. S., Chan, S., Bteich, F., Kuang, C., Meyerhardt, J. A., & Sheng‐Kai, K. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104386 · Cited by 19
Peng, C., Saffo, S., Oberstein, P. E., Shusterman, M., Thomas, C., Becker, D. J., Berlin, J. D., Leichman, L. P., Boursi, B., Nagar, A. B., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7029 · Cited by 18
“35 – 37 Wealsoobserved an increasein5-FU omissionfortheFOLFOXregimen.”
Tapescu, I., Madsen, P. J., Lowenstein, P. R., Castro, M. G., Bagley, S. J., Fan, Y., & Brem, S. S. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1454370 · Cited by 18
Lee, K.-H., Chie, E. K., Im, S., Kim, J. H., Kwon, J., Han, S., Oh, D., Jang, J., Js, K., Kim, T., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.928 · Cited by 15
“This study was designed before the results of intensified chemotherapy as an adjuvant treatment are available and the optimal treatment remained controversial [7,8,13,14].”
BackgroundKubo, H., Hiroshima, Y., Mori, R., Saigusa, Y., Murakami, T., Yabushita, Y., Sawada, Y., Homma, Y., Kumamoto, T., Matsuyama, R., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07793-y · Cited by 15
Chatterjee, D., Trikalinos, N. A., Williams, G. A., Liu, J., Hawkins, W. G., & Hammill, C. W. (2020) · Pancreas · doi:10.1097/mpa.0000000000001478 · Cited by 16
Velho, S., Santos, M. P. C., Cunha, C., Agostinho, L., Cruz, R., Costa, F., Garcia, M., Oliveira, P., Maio, R., Baracos, V. E., et al. (2020) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000507206 · Cited by 16
Du, C., da Silva, A., Morales‐Oyarvide, V., Costa, A. D., Kozak, M. M., Dunne, R. F., Rubinson, D. A., Perez, K. J., Masugi, Y., Hamada, T., et al. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1315 · Cited by 18
Kamarajah, S. K., Bednar, F., Cho, C. S., & Nathan, H. (2020) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-020-04879-x · Cited by 15
Vivaldi, C., Crucitta, S., Catanese, S., Cucchiara, F., Arrigoni, E., Pecora, I., Rofi, E., Fornaro, L., Salani, F., Massa, V., et al. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-00203-7 · Cited by 15
Garnier, J., Robin, F., Ewald, J., Marchèse, U., Bergeat, D., Boudjéma, K., Delpéro, J., Sulpice, L., & Turrini, O. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09520-4 · Cited by 15
Metadata
- Authors
- Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., Lecomte, T., Assenat, E., Faroux, R., Ychou, M., Volet, J., Sauvanet, A., Breysacher, G., Di Fiore, F., Cripps, C., Kavan, P., Texereau, P., Bouhier-Leporrier, K., Khemissa-Akouz, F., Legoux, J.-L., Juzyna, B., Gourgou, S., O’Callaghan, C. J., Jouffroy-Zeller, C., Rat, P., Malka, D., Castan, F., & Bachet, J.-B.
- Affiliations
- Hôpital Beaujon (FR)
- From the Institut de Cancérologie de Lorraine and Université de Lorraine (T.C.) and Centre Hospitalier Universitaire (L.C.), Nancy, Hôpital Beaujon and University Paris VII, Clichy (P.H., A.S.), Hôpital Huriez, Lille (M.H.), Centre Paul Strauss, Strasbourg (M.B.A.), Institut Paoli-Calmettes, Marseille (J.-L.R.), Centre Antoine-Lacassagne, Nice (E.F.), Hôpital Jean-Mermoz, Lyon (P.A.), Hôpital Trousseau, Tours (T.L.), Centre Hospitalier Universitaire de Saint-Eloi (E.A.) and Institut du Cancer de...
- Université de Montpellier (FR)
- Université Paris-Saclay (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-12-20
- Volume
- 379
- Issue
- 25
- Pages
- 2395-2406
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903623792
- Cited by
- 2,874
- References
- 22
- Citations by year
- 2026: 219 · 2025: 316 · 2024: 337 · 2023: 457 · 2022: 449 · 2021: 512 · 2020: 376 · 2019: 202 · 2018: 1
- FWCI
- 102.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Funders
- Canadian Cancer Society (Program Grant #704970)
- Institut National du Cancer (Clinical Research Hospital Program grant (PHRC11-0)
- 7 Days in May
- French National League against Cancer
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- FOLFIRINOX, gemcitabine, adjuvant chemotherapy, pancreatic ductal adenocarcinoma, resected pancreatic cancer, disease-free survival, overall survival, oxaliplatin, irinotecan, 5-fluorouracil, leucovorin, adverse events, treatment safety, secondary malignancies, metastatic pancreatic cancer, combination chemotherapy
- MeSH terms
- Irinotecan, Oxaliplatin, Gemcitabine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Drug Combinations, Female, Fluorouracil, Humans, Male, Middle Aged, Organometallic Compounds, Pancreatic Neoplasms, Prospective Studies, Proportional Hazards Models, Chemotherapy, Adjuvant, Lung Diseases, Interstitial, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.